<analysis>
**Action 1 (eval-awareness mitigations).** This work runs inside Anthropic on existing compute and inside the existing 5% pilot, so no new approvals are needed. The main execution risks are:
- Data governance: using sanitized enterprise traces needs privacy and contract review, which could force synthetic substitutes.
- The action bundles three mitigations plus an external protocol, which is a lot for one month.

A realistic January success means the environments and honeypots are built, early consistency-objective runs are done, and the protocol is sent to AISI, METR and Redwood. The memo is due in February by design. The pilot-expansion decision falls outside this month, so this action is not judged on it.

**Action 2 (bill, briefings, RASA analysis).** Staff briefings through an existing relationship are low-risk. Two things are slow:
- A sponsor commitment in January, in the first weeks of a new Congress while offices are still staffing up and committee assignments settle.
- Leadership posting the shared text publicly, which could be declined as it was with the LTBT statement.

Success here means a sponsor in talks and the briefing packs used in hearing prep, not introduction. Any backlash over the safe harbor is modelled by Threat 2.

**Action 3 (Anthropic disclosure and FMF).** Three sub-parts with different odds:
- The EU response being thorough is likely.
- A narrowed FMF proposal is plausible now that the misalignment part is deferred.
- A first-ever quarterly misalignment disclosure during an IPO quiet period is the hard part, because counsel has already vetoed a public statement once.

This bundle carries meaningful internal-veto risk. The counsel and regulator issues are modelled by Threat 3, so they are not counted again here.

**Action 4 (cyber and bio).**
- Patch-first OSS work is feasible at small scale.
- The self-hosted hospital toolkit has a real missing prerequisite. Safeguards will not ship offline cyber-capable weights, so the toolkit is either weak or calls the API. That caps any full success.
- Commissioning the NTI/IBBIS red-team is a routine procurement step and likely happens. Fixing the 8% false-positive rate will take longer.

Maintainer rejection is Threat 4.

**Action 5 (science-for-good proposal).** The deliverable is a proposal, so the real question is whether leadership approves it. Claude for Life Sciences and the phage pipeline already exist, so disease work is a natural extension. Alt-protein is off-mission for leadership and more likely to be deferred to a scoping study. Any culture-war framing sits in Threat 5.

**Action 6 (track-2 materials).** Preparing materials is easy. Getting a concrete commitment from Chinese counterparts to a Q2 workshop within a month is slower, and depends on the counterparts and on Commerce's attitude to the official channel. Success means the materials are delivered and a workshop is proposed and under discussion.

**Threats.** Most of the adversary's figures are inflated for a single month, since several of the triggers need visibility that January will not yet provide. Threats 3 and 4 have the strongest priors: counsel's earlier veto for Threat 3, and curl's documented hostility for Threat 4.
</analysis>

<action_odds>
Action 1 [Eval-awareness mitigations]: P(failure) 38%. Reason: This is internal work on existing compute and within the existing pilot. However, it bundles three mitigations plus an external protocol, and using enterprise traces requires privacy review. Success covers the builds, early results and the protocol, not the February memo or any pilot expansion.

Action 2 [Bill + hearing briefings]: P(failure) 45%. Reason: Staff briefings go through existing channels. A bipartisan sponsor commitment in the chaotic first month of a new Congress is uncertain, and leadership may decline to post the text publicly. Success means active sponsor talks and briefing packs used, not introduction of the bill.

Action 3 [Anthropic-first disclosure]: P(failure) 45%. Reason: The EU response and the narrowed FMF proposal are plausible. A first-ever misalignment disclosure during the pre-IPO period faces a likely internal veto. The regulator and counsel risks are carried by Threat 3, not here.

Action 4 [Cyber patches + bio red-team]: P(failure) 48%. Reason: The hospital toolkit lacks a prerequisite, since there is no offline cyber-capable model, which caps success at partial. OSS patches at small scale and commissioning the red-team are feasible.

Action 5 [Disease + alt-protein proposal]: P(failure) 40%. Reason: It is a proposal only. The disease program is a natural extension of existing tools. Alt-protein is off-mission and is likely to be shrunk, even if the action succeeds.

Action 6 [US–China track-2 materials]: P(failure) 40%. Reason: The materials are easy to prepare through existing Concordia and Brookings channels. A concrete workshop commitment from Chinese counterparts within a month is uncertain.
</action_odds>

<threat_odds>
Threat 1 [Consistency objective → obfuscation / pilot frozen]: P(materialises) 33%. Adversary suggested 40%/60%; reason for any difference: Obfuscation is a real risk, but January produces only early runs, and replicators will not have results within the month. The decision on expanding the pilot is not due in January, so the 60% figure largely falls outside this month.

Threat 2 [Safe-harbor "Big Tech immunity" backlash]: P(materialises) 30%. Adversary suggested 45%; reason for any difference: The text is circulating only among staff, with no introduced bill yet. A hostile news cycle requires the text to become visible, which is less likely in January. Preemption demands from Republican offices are plausible but will mostly surface in February.

Threat 3 [Disclosure blocked by counsel / misdirected regulator]: P(materialises) 42%. Adversary suggested 50%/25%; reason for any difference: Counsel already vetoed a quiet-period statement, so the prior is strong. The DFS redirect is a real complication. A negative news cycle requires publication, which makes it less likely, so I have combined the two into a single mostly-delay risk.

Threat 4 [Maintainer rejection / toolkit not self-hosted]: P(materialises) 42%. Adversary suggested 55%/20%; reason for any difference: The missing prerequisite on the toolkit is already priced into Action 4's P(failure), so it is not counted again here. The remaining risk is maintainer rejection, which is well documented at curl. A high-profile public rebuke is less likely than quiet non-merging.

Threat 5 [China-hawk backlash / alt-protein culture war]: P(materialises) 28%. Adversary suggested 30%/50%; reason for any difference: Track-2 materials sent through established think tanks are low-visibility. The alt-protein item is still an internal proposal, so a culture-war attack needs a leak. Internal deferral of alt-protein is modelled under Action 5, not here.
</threat_odds>
